Christopher is an established leader in molecular diagnostics for urology and oncology. He has led team initiatives that successfully established operations, launched innovative products, delivered clinical validation, gained guideline inclusion, secured reimbursement, and generated clinical adoption.

With a track record of leadership in the fields of urology and oncology, Laura is leveraging her experience to redefine the early detection of bladder cancer. With a deep understanding of the clinical landscape, Laura is dedicated to fostering innovation and delivering on the promise of improving patient care and clinical outcomes.

As a former professor (Huntsman Cancer Institute) and fellowship-trained urologic oncologist (Vanderbilt, MSKCC, Harvard), Dr. Lowrance has led clinical trials in bladder cancer and helped shape clinical guidelines. His current practice and research efforts focus on improving clinical care and outcomes for patients. Dr. Lowrance has published numerous peer-reviewed urologic articles, book chapters, and editorials.

With a PhD in Epigenetics, Dr. Krispin has successfully developed and validated numerous molecular diagnostic assays, particularly in DNA-methylation analysis, genotyping, NGS assays, and multiplex PCR. Dr. Krispin was pivotal in the design of Vesica's AssureMDx test.